SciTech Development is a Specialty Pharmaceutical Company dedicated to advancing breakthrough cancer treatments. SciTech’s innovations and pipeline will impact our mission to develop cost-effective therapeutics that deliver transformative clinical outcomes. SCITECH DEVELOPMENT LLC Introducing Our Revolutionary New Drug Delivery Platform (SDP) and Lead Cancer Drug Candidate ST-001 nanoFenretinide. ● Our proprietary Drug Delivery Platform, called SDP, has enormous potential to develop and deliver new and better drugs for incurable cancers. ● ST-001-nanoFenretinide is our first, patented drug, that combines SDP and the drug fenretinide as a broadly applicable anticancer drug. ● Fenretinide presents a low-risk scenario as it has been shown to be safe and effective in both children and adults in previous clinical trials. ● ST-001 is clinical trial ready! OUR GOAL Our immediate goal is to commercialize ST-001 and develop strategic partnerships with companies in the pharmaceutical industry who are looking to expand their existing drug portfolio in oncology, target new diseases, or develop combination drug therapies. OUR HIGHLIGHTS AND ACHIEVEMENTS • IND for T-Cell Lymphomas approved by the FDA • FDA approved Phase 1a/b (equivalent to traditional Phase 1 & 2) clinical trial plan • IRB Approved by Rush University Medical Center to start clinical trials • Orphan Drug Designation granted for several T-cell lymphomas • SDP can be used to solve bioavailability and delivery issues in many other drugs • SDP has potential application for treating additional cancers and other diseases • ST-001 has potential use as a companion therapeutic with other already approved drugs • Affordable treatment cost to patients and for payors